Pioneering biologics with precision—to redefine treatment for millions
Fortvita is focused on investigating biologics with smarter design and agile innovation, with the goal of translating next-generation therapies from concept to clinic.
What We Do
Pursuing scientific solutions for global healthcare needs
Antibody innovation is central to our mission to advance biologic therapies for patients worldwide. Through protein engineering, structure-based drug design, and bispecific antibody technologies, we are investigating next-generation treatments aimed at addressing limitations of current standards of care. Our global vision is to make groundbreaking science accessible, turning research into real-world solutions that improve health outcomes for those who need them most.
At Fortvita, we advance next generation breakthrough biologic therapies with the aim of improving patient outcomes and addressing unmet medical needs.
In oncology, we are developing next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) platforms. Our approach integrates protein engineering, structure-based drug design, and polyspecific antibody technologies to pursue targeted and durable treatment strategies for patients with cancer.
Building on this foundation, we are expanding our R&D efforts beyond oncology and into cardiovascular and metabolic (CVM) diseases, applying Fortvita’s scientific rigor and platform capabilities to areas of growing global health burden.
Our goal is simple: to translate cutting-edge science into meaningful therapeutic solutions and contribute to better health for patients worldwide.
Pipelines
Pipelines designed with focused innovation
Our pipeline reflects a strategic and focused approach to innovation, advancing programs that explore novel mechanisms in immunotherapy and targeted delivery. Current assets include bispecific antibodies and antibody-drug conjugates (ADCs) directed at PD-1, IL-2, DLL3, CLDN18.2 and other emerging targets, with clinical and preclinical development spanning multiple tumor types including lung, gastric, pancreatic, colorectal, and melanoma.
Our Mission
Transforming research breakthroughs into therapeutic excellence
We’re a biopharmaceutical company headquartered in the San Francisco Bay Area, with a global mission to redefine the future of cancer care. By pioneering antibody discovery and engineering, we aim to unlock powerful new treatment pathways and set new standards in patient care.
Our clinical development footprint includes the U.S. and Australia, as well as key regions across APAC and Europe—including the EU, UK, South Korea, and Japan—where we are advancing investigational therapies for some of the most challenging cancers, including lung, pancreatic, and gastroesophageal malignancies. United by a vision to change the trajectory of disease, we are committed to delivering targeted, impactful solutions that benefit patients worldwide.
